At Heligenics, we produce all genetic variants for a given gene and test how all those variants functionally impact, en masse, live human cells.
We are the first company to enable High Content Screening for Biologics
.png){kind=logo}
™
Accurate diagnostics with precision Biomarkers
Genetic Biomarkers are particularly useful for diagnoses and therapeutics. However, most approved drugs have a single variant Biomarker. Heligenics offers Whole Gene Biomarkers, where a diagnosis can be based upon all variants with similar activity to an established Biomarker.
​
Whole Gene Biomarkers examine all the mutations in a gene rather than a single mutation. This is a natural conceptual expansion of what is already in common clinical practice.
Five Facts
-
Steady growth in genetic Biomarkers over the last decade
-
There are 100s of genetic Biomarkers
-
Genes have many variants with the same activity as known Biomarkers
-
Whole Gene Biomarkers expand the number of customers eligible for a drug
-
Drug resistance mutations for a whole gene are useful
Treatments based on one genetic marker have medical advantages
Why use one genotype when you can use a Whole Gene Biomarker?
-
46% of total recent approvals
-
One mutation as a Biomarker
From “The Personalized Medicine Report: 2017 Opportunity, Challenges, and the Future”.
http://www.personalizedmedicinecoalition.org
One Size Does Not Fit All
Percentage of the patient population for which a particular drug is NOT effective
Anti-Depressants (SSRIs) 38%
Asthma Drugs 40%
Diabetes Drugs 43%
Arthritis Drugs 50%
Alsheimer’s Drugs 70%
Cancer Drugs 75%
Whole Gene Biomarker
Example of patients with Single Mutation Biomarker identified versus using MEGA-Map™ Whole Gene Biomarker panel
Single Mutation
Biomarker
MEGA-Map™ Whole Gene Biomarker
Disease, but lack Single
Mutation Biomarker
Disease with Whole Gene
Biomarker
Disease with Single Mutation
Biomarker